Abstract
Parkinson’s disease (PD) is the world’s second most common neurodegenerative disease that is associated with age. With the aging of the population, patients with PD are increasing in number year by year. Most such patients lose their ability to self-care with disease progression, which brings an incalculable burden to individual families and society. The pathogenesis of PD is complex, and its clinical manifestations are diverse. Therefore, it is of great significance to screen for circulating biomarkers associated with PD to reveal its pathogenesis and develop objective diagnostic methods so as to prevent, control, and treat the disease. In recent years, microRNAs (miRNAs) and long non-coding RNAs (lncRNAs) are considered to be effective biomarkers for various diseases due to their stability, and resistance to RNAase digestion and extreme conditions in circulating fluids. Here, we review recent advances in the detection of abnormally expressed miRNAs and lncRNAs in PD circulating fluids, and discuss the function and molecular mechanisms of plasma or serum miR-124, miR-132, miR-29, miR-221, miR-7, miR-433, and miR-153 in the regulation and progression of PD. Additionally, application of the differential expression of lncRNAs in circulating fluid in the pathological progression and diagnosis of PD is also reviewed. In short, the determination of abnormally expressed circulating miRNAs and lncRNAs will be valuable for the future diagnosis and treatment of PD.
Highlights
Parkinson’s disease (PD) is the world’s second most common neurodegenerative disease associated with aging, with an incidence close to 1% in people over 60 years of age (Elbaz et al, 2016)
Their study showed that miRNAs were specific to brain regions. These results suggested that the changes in miRNA levels in circulating biological fluids may be related to the changes in miRNA levels in the brain
In a PD mouse model, Metastasisassociated lung adenocarcinoma transcript 1 (Malat1) binds miR-129 and down-regulates its expression, thereby eliminating the inhibition of SNCA gene expression by miR-129. This suggests that the Malat1/miR-129/SCNA pathway plays an important role in PD development (Xia et al, 2019)
Summary
Parkinson’s disease (PD) is the world’s second most common neurodegenerative disease associated with aging, with an incidence close to 1% in people over 60 years of age (Elbaz et al, 2016). It is believed that motor dysfunction, such as rigidity, postural instability, tremor and bradykinesia, is related to a decrease in dopaminergic neurons in the striatum (Tysnes and Storstein, 2017). This is one of the most prominent pathological features of PD. Due to the complicated pathogenesis of this disease, clinical symptoms and signs between different patients may be distinct, with impaired motor functions usually occurring a few years after the onset of disease. Screening for PD-related biomarkers is of great significance in revealing disease pathogenesis and developing objective diagnostic methods to prevent and treat disease. This review analyzes the relationship between ectopically expressed micro(mi)RNAs and long non-coding (lnc)RNAs in circulating fluids and patients with PD, and provides strong evidence for finding new PD biomarkers and therapeutic targets
Sign-in/Register to view highlights & summary Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
